ABT241227P103000
- 0.11
- 0.000.00%
Abbott Laboratories Newsroom
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Abbott Laboratories (NYSE:ABT) Is Largely Controlled by Institutional Shareholders Who Own 77% of the Company
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Laboratories' (NYSE:ABT) Investors Will Be Pleased With Their Respectable 43% Return Over the Last Five Years
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Express News | Abbott : TD Cowen Raises Target Price to $135 From $130
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Abbott Laboratories (ABT) Gets a Buy From Piper Sandler
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year